Cardiothoracic surgery - 10 News from the research and development department for the pharma industry

Tip: You can further refine your news selection by organizations and countries.

Cardiothoracic surgery - 10 News from the research and development department for the pharma industry

Tip: You can further refine your news selection by organizations and countries.

Action Pharma’s phase IIb clinical trial with AP214 to prevent kidney injury demonstrates positive top-line results

28-Sep-2011 - Action Pharma A/S announced positive top-line results for its phase IIb AP214 trial in patients undergoing major cardiac surgery. The study demonstrated that AP214 is safe, reduces kidney injury, and improves long-term (90 days) outcomes on a composite end point (death, dialyses and kidney ...

cardiothoracic surgery acute kidney injury phase IIb studies

Last patient completes last visit in Action Pharma’s phase IIb clinical trial with AP214 to prevent kidney injury associated with major cardiac surgery

09-Aug-2011 - The final patient has performed the last visit of the study period in Action Pharma’s US and Denmark based phase IIb study. Treatment with AP214 is designed to investigate whether acute kidney injury can be prevented in patients undergoing major cardiac surgery – a serious unmet medical need with ...

cardiothoracic surgery acute kidney injury phase IIb studies

Endotis Pharma reports successful completion of the neutralization study of the anticoagulant EP217609 by avidin

17-Nov-2010 - Endotis Pharma announced that it has successfully completed the first study assessing in healthy subjects the neutralization of the anticoagulant EP217609 by its specific antidote avidin. EP217609 and avidin were well tolerated in the 36 healthy subjects enrolled in this study. A single ...

cardiothoracic surgery clinical trials Neutralization

Action Pharma initiates phase IIb clinical trial with AP214 to prevent kidney injury associated with major cardiac surgery

10-Nov-2010 - Action Pharma A/S has administered the first dose to the first patient in a phase IIb clinical trial being undertaken in the USA and Denmark with its leading drug candidate AP214. This follows the positive results obtained on safety, tolerability and efficacy in the phase IIa clinical trial ...

cardiothoracic surgery acute kidney injury clinical trials

Action Pharma obtains positive results in a phase II clinical trial with AP214

15-Sep-2010 - Action Pharma A/S has obtained positive safety, tolerability and efficacy results in the second phase II clinical trial (CS005) with its leading development candidate, AP214. AP214 is being developed for protection of acute kidney injury (AKI) in patients undergoing cardiac surgery under ...

cardiothoracic surgery acute kidney injury clinical trials

Endotis Pharma presents Phase I clinical trial results for a first-in-class synthetic parenteral neutralizable anticoagulant

09-Jul-2010 - Endotis Pharma announced that Phase I clinical trial results for EP217609 were presented at the 21st International Congress on Thrombosis (ICT) in Milan, Italy. EP217609 is a first-in-class synthetic, parenteral anticoagulant which can be neutralized by a specific antidote, avidin. EP217609 has a ...

cardiothoracic surgery clinical trials Italy

Action Pharma obtains encouraging preliminary results in a phase II clinical trial with AP214

09-Jun-2010 - Action Pharma A/S obtained encouraging preliminary blinded results in the second phase II clinical trial (named CS005) with its lead development candidate, AP214. AP214 is being developed for protection of acute kidney injury in patients undergoing cardiac surgery under cardiopulmonary bypass as ...

cardiothoracic surgery acute kidney injury clinical trials

Action Pharma completes dosing in phase II clinical trial with AP214 to prevent acute kidney injury

30-Mar-2010 - Action Pharma A/S has completed dosing in the second phase II clinical trial with its leading development candidate, AP214. Interim efficacy data are expected June 2010. AP214 is being developed for protection of acute kidney injury in patients undergoing cardiac surgery under cardiopulmonary ...

cardiothoracic surgery acute kidney injury clinical trials

Action Pharma in new phase II clinical trial on organ protection in patients undergoing cardiac surgery

22-Oct-2009 - Action Pharma has initiated a new clinical phase II trial for it's leading development candidate AP214, investigating the effect of AP214 on organ protection in patients undergoing cardiac surgery, who are at increased risk of kidney injury. The clinical trial has been launched in Denmark at ...

cardiothoracic surgery clinical trials Denmark

Neuren launches Phase 3 Trial in NZ

17-Sep-2007 - Neuren Pharmaceuticals has launched the New Zealand arm of its Phase 3 trial of Glypromate®, one of the first compounds developed in New Zealand by a New Zealand company to enter a global Phase 3 clinical trial. Glypromate® has been developed by the ASX-listed company to protect brain function, ...

cardiothoracic surgery brain functions clinical trials
Haven't found the right news yet?

The bionity.com news search

Start your targeted search now with a wide range of filter options. Our database includes an archive of 27,276 life science news from business and science, which you can search by topic and organization, filtered by time and geography.

Start news search now